The Food and Drug Administration has approved Shire's application to market Vyvanse as a treatment for moderate-to-severe binge eating disorder in adults.
The drug is already approved for use in patients with attention deficit hyperactive disorder.
"Binge eating disorder is the most common adult eating disorder in the United States," said Philip J. Vickers, global head of research and development at Shire, in a prepared statement. "This new indication for Vyvanse is a critical milestone in the treatment of this condition, and reflects our ongoing commitment to address the needs of patients."
For more business go to PBJ.com.
Copyright bizjournal
